<DOC>
	<DOCNO>NCT00530855</DOCNO>
	<brief_summary>This open-label extension trial ass long-term use Lacosamide monotherapy safety Lacosamide monotherapy adjunctive therapy subject partial-onset seizure previously enrol conversion monotherapy trial ( SP902 ) .</brief_summary>
	<brief_title>Trial Assess Long-term Lacosamide ( LCM ) Monotherapy Use Safety LCM Monotherapy Adjunctive Therapy Partial-onset Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Subject enter Maintenance Phase doubleblind trial , SP902 , ( ie , take least 1 dose SP902 Maintenance Phase trial medication ) either complete SP902 meet exit criterion SP902 ; subject allow 2 concomitant Antiepileptic Drugs ( AEDs ) Subject meet withdrawal criterion ( exclude exit criterion ) SP902 trial , experience ongoing Serious Adverse Event ( SAE )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Partial-onset Seizures</keyword>
	<keyword>Lacosamide</keyword>
	<keyword>Monotherapy</keyword>
	<keyword>Vimpat</keyword>
</DOC>